With Flu and Other Conditions in the Future
Established more than 10 years ago, Cue Health’s goal is still to make healthcare more accessible and actionable by building the most advanced at-home diagnostic system that delivers lab-quality test results to customers’ mobile device. Their testing kit has been used throughout the COVID-19 pandemic by organizations such as the MLB, NBA, and NASA, just to name a few.
Now, Cue is continuing to make a difference in the lives of people with the launch of Cue Care, its same-day, at-home, test-to-treatment solution. Patients who test positive for COVID-19 will now be able to consult a doctor and receive medication within a few hours of receiving their test results.
“Getting treatment for COVID today is cumbersome and confusing. If you test positive, getting medication is very challenging…We wanted to change that,” said a spokesperson for Cue Health. “Being able to get a test result and immediately turn it into a prescription that gets delivered is a big innovation in healthcare.”
The Cue Care antiviral delivery service costs between $79 and $99 and includes a televisit with a healthcare professional and delivery of medication, the cost of which is currently covered by the U.S. Department of Health and Human Services.
“Early diagnosis and treatment have shown to lead to better health outcomes, which is why we’re proud to deliver timely testing and treatment, all within the Cue Health App,” said Ayub Khattak, chairman and CEO of Cue Health. “Cue Care meets the need today for convenient delivery of COVID-19 treatment, and this capability will support our expanding pipeline of future diagnostics tests.”
While Cue Care covers COVID-19 today, the Cue Health app was built to enable seamless integration with tests in Cue’s pipeline, including the flu molecular test.
Cue recently announced it made a de novo submission to the U.S. Food and Drug Administration for full clearance of the Cue Flu Molecular Test for at-home and point-of-care use. Once approved by the FDA, the Cue Flu Molecular Test will be the first at-home and point of care molecular flu test that has been fully reviewed by the FDA for safety and efficacy.
The cartridge uses a lower nasal swab and is compatible with the Cue Reader, which communicates test results digitally via Bluetooth to a mobile device in approximately 25 minutes. “The test, if authorized by the FDA, will be integrated into the Cue Care service, seamlessly connecting healthcare providers to patients, while limiting community exposure and disease transmission by identifying and treating ill individuals in their own home,” said the spokesperson.
“We’re just getting started. We want to make the Cue Care service as accessible as possible and this level of integration and speed of delivery is a breakthrough innovation in healthcare, which will expand to other tests over time, like influenza, strep throat, and sexual health tests for chlamydia and gonorrhea, and more.”
For more Information Contact:
Larry Vaupel Economic Development Director, City of Vista
P: 760.643.5244 E: firstname.lastname@example.org